Clinical trial · Expanded Access
Expanded Access to RXDX-105 for Cancers With RET Alterations
Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations
NCT03052569CI-TRIAL-00038348no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancers With RET Alterations | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RXDX-105 | Drug | Agerafenib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of advanced cancer with RET alterations * Unable to participate in an ongoing RXDX-105 clinical trial * Willing and able to provide written, signed informed consent * Medically suitable for treatment with RXDX-105 Exclusion Criteria: * Prior treatment with a TKI that has activity against RET alterations * Currently enrolled in an ongoing clinical study with any other investigational agent
References
Publications (0)
Data not yet available
No reference posted for this study.